The role of excipients of trometamolum and meglumine in the formation of biopharmaceutical properties of medicinal products of various pharmacites

Keywords: biopharmaceutical factors, pH regulators, chemical modification, meglumine, trometamolum, solubility, bioavailability

Abstract

At the present stage of development of the pharmaceutical industry, the use of many functional excipients (DopR), which are important components of pharmaceutical formulations, becomes relevant. DopR is one of the most influential biopharmaceutical factors on the therapeutic efficacy of drugs, increasing the therapeutic effect and safety of active pharmaceutical ingredients (APIs) through the formation of optimal compounds and appropriate dosage forms by chemical modification of the molecule responsible for pharmacological activity.

The purpose of the work is to analyze the literature on determining the role of excipients of trometamol and meglumine as biopharmaceutical factors in drugs of different pharmacotherapeutic groups; summarize and systematize data on their impact on the bioavailability of finished drugs.

The objects of the study are excipients trometamоlum (TНAM) and meglumine (MGA) in the composition of drugs of different pharmacotherapeutic groups. Methods of a systematic approach, bibliographic, information retrieval, generalization and analysis were used in the research.

A systematic study of the composition of drugs of the State Register of Medicinal Products (January 2021) showed that chemically modified drugs are supplied to the pharmaceutical market not only by domestic manufacturers, but also by pharmaceutical companies from 16 countries. The general nomenclature of drugs makes 82 trade names, from them 66% – with TMM and 34% – with MGA.

A significant number of chemically modified insoluble and sparingly soluble APIs of different pharmacotherapeutic groups indicates a significant role of TMM and IGA in the development of new effective drugs.

Thus, organic aminoproton acceptors: trometamol and meglumine – many functional excipients that increase the activity of active molecules, their release from dosage forms, stimulate the pharmacotherapeutic effect of drugs aimed at activating the protective forces (sanogenesis) and compensatory mechanisms of the body and thus, improve the pharmacological properties of drugs, reduce the risk of adverse reactions.

References

Elder D., Kuentz M., Holm R. Pharmaceutical excipients — quality, regulatory and biopharmaceutical considerations. // Europ. J. Pharmac. Sci. – 2015. – V. 87. – P. 88–99. https://doi.org/10.1016/j.ejps.2015.12.018

Vlasenko I. O., Davtian L. L. Active pharmaceutical ingredients in dermatological medicines of Ukrainian pharmaceutical market // Farmats. zhurn. ‒ 2019. ‒ № 1. ‒ S. 9‒19. https://doi.org/10.32352/0367-3057.1.19.01

Van der Merwe J., Steenekamp J., Steyn D. et al. The Role of Functional Excipients in Solid Oral Dosage Forms to Overcome Poor Drug Dissolution and Bioavailability // Pharmaceutics. ‒ 2020. ‒ V. 12, N 5. ‒ P. 393. https://doi.org/10.3390/pharmaceutics12050393. PMID: 32344802; PMCID: PMC7284856.

Ruban O. A., Pertsev I. M., Kutsenko S. A. ta in. Dopomizhni rechovyny u vyrobnytstvi likiv: navch.posib. dlia studentiv vyshch. farmats. navch. zakl. – Kharkiv: Zoloti storinky, 2016. – 720 s.

Elder D., Faïs F. Allowable levels of excipients in drug products // Europ. Pharmac. review. – 2019. – № 4 [Електронний ресурс]. ‒ Режим доступу: https://www.europeanpharmaceuticalreview.com/article/98178/allowable-levels-of-excipients-in-drug-products/

Abrantes Cátia G., Dinah Duarte, Catarina Pinto Reis. An Overview of Pharmaceutical Excipients: Safe or Not Safe? // J. Pharmac. Sci. – 2016. – V. 105, Iss. 7. – P. 2019–2026. https://doi.org/10.1016/j.xphs.2016.03.019

Palchevska T. A., SalIy O. O., Baula O. P., Palchevskiy K. V. Meglyumin ta yogo soli: vlastivostI ta perspektivi vikoristannya u farmatsiyi // Farmats. chasopis. – 2020. – № 2. – S. 92–100. https://doi.org/10.11603/2312-0967.2020.2.11194

Kovalenko A. L. Farmakolohycheskaia aktyvnost oryhynalnikh lekarstvennikh preparatov na osnove 1-dezoksy-1(N-metylamyno)-D-hliutsytola: Avtoref. dys. … d-ra biol. nauk: 14.00.25. ‒ Sankt-Peterburh, 2005. ‒ 48 s.

El-Harakany A. A., Abdel Halima F. M., Barakat A. O. Dissociation constants and related thermodynamic quantities of the protonated acid form of tris-(hydroxymethyl)-aminomethane in mixtures of 2-methoxyethanol and water at different temperatures // J. Electroanal. Chem. – 1984. – V. 162, N 1‒2. ‒ P. 285‒305. https://doi.org/10.1016/S0022-0728(84)80171-0

Iakovenko І. N., Abdurakhmanova E. R., Holovchenko O. V. et al. The synthesis and study of vasoactive properties of new 4-functionaliz // J. Organic Pharmac. Chem. – 2017. – V. 15, N 3 (59). https://doi.org/10.24959/ophcj.17.921

Sandeep Kalepua, Vijaykumar Nekkantib. Insoluble drug delivery strategies: review of recent advances and business prospects // Acta Pharmac. Sinica B. – 2015. – V. 5, Iss. 5.– P. 442–453. https://doi.org/10.1016/j.apsb.2015.07.003

Abu T. M. Serajuddin. Salt formation to improve drug solubility // Advanced Drug Delivery Rev. – 2007. – V. 59, Iss. 7. – P. 603–616. https://doi.org/10.1016/j.addr.2007.05.010

Lin Zhong, Xingyi Zhu, Bo Yu, Weike Su. Influence of alkalizers on dissolution properties of telmisartan in solid dispersions prepared by cogrinding // Drug Dev. Industrial Pharmacy. – 2014. – V. 40, N 12. – P. 1660‒1669. https://doi.org/10.3109/03639045.2013.841188

Mandić Z., Gabelica V. Ionization, lipophilicity and solubility properties of repaglinide // J. Pharmac. Biomed. Analysis. – 2006. – V. 41. – P. 866‒871. https://doi.org/10.1016/j.jpba.2006.01.056

Kallet R. H., Jasmer R. M., Luce J. M. et al. The treatment of acidosis in acute lung injury with tris-hydroxymethyl aminomethane (THAM) // Am. J. Respir. Crit. Care Med. – 2000. – V. 161, N 4, Pt. 1. – Р. 1149–1153. https://doi.org/10.1164/ajrccm.161.4.9906031

Luckas M., Bricker L. Intravenous prostaglandin for induction of labour // Cochrane Database Syst. Rev. – 2000. – V. 4. ‒ CD002864. https://doi.org/10.1002/14651858.CD002864. PMID: 11034778

Derzhavnyi reiestr likarskykh zasobiv [Elektronnyi resurs]. – Rezhym dostupu: http://www.drlz.com.ua

Liapunov N. A., Liapunov A. N., Zynchenko Y. A. Farmatsevtycheskaia kompozytsyia dlia naruzhnoho prymenenyia, soderzhashchaia sol deksketoprofena, y sposob ee poluchenyia. Pat. RU (11) 2 667 465 (13) C2 MPKA61K 31/19 (2006.01) A61K 9/06 (2006.01) A61K 47/20 (2006.01) A61K 47/10 (2006.01) A61P 19/02 (2006.01). Zaiavka: 2015146420, 28. 10. 2015. Data rehystr. 19. 09. 2018. – ZAO «FarmFyrma "Soteks"».

Liapunov A. N., Bezuhlaia E. P., Zynchenko Y. A. Analytycheskoe obespechenye razrabotky tekhnolohycheskoho protsessa helia meloksykama / Farmakom. – 2015. – № 3/4. – S. 29‒38 [Elektronnyi resurs]. ‒ Rezhym dostupu: http://sphu.org/wp-content/uploads/2017/01/Farmacom_3_4_2015.pdf

Kalepu S., Nekkanti V. Insoluble drug delivery strategies: review of recent advances and business prospects. // Acta Pharm. Sin. B. – 2015. – N 5 (5). – Р. 442–453.

Toshimitsu O., Manabu N., Savada T., Kenzo T. Farmatsevtychna kompozytsiia, yaka vkliuchaie telmisartan, sposib yii oderzhannia (varianty), dvosharova farmatsevtychna tabletka ta sposib yii oderzhannia. Pat. na vynakhid Ukraina: MPK(2006): A61K 9/16, A61K 9/20, A61K 31/4184 (2006.01) A61P 9/12 (2006.01) № UA 81781 S2; Zaiavl 24.09.2002; Opubl. 11.02.2008.

Mur R. Е., Barden Dzh. Systematycheskyi obzor deksketoprofena pry ostroi y khronycheskoi boly // Nevrolohiia. Dokazova medytsyna. ‒ 2010. ‒ № 10 (239). ‒ S. 52‒55 [Elektronnyi resurs]. ‒ Rezhym dostupu: http://health-ua.com/pics/pdf/2010_10/52-55.pdf

Nikonov V. V., Lyzohub K. I., Lyzohub M. V. Zastosuvannia deksketoprofenu v suchasnykh pidkhodakh do multymodalnoi analhezii // Medytsyna nevidkladnykh staniv. – 2020. – T. 16, № 5. – S. 34‒38. https://doi.org/10.22141/2224-0586.16.5.2020.212221

Verlan N. V. Perspektyvi kupyrovanyia posleoperatsyonnoho bolevoho syndroma: prymenenye ketorolaka / Statsyonarozameshchaiushchye tekhnolohyy: ambulatornaia khyrurhyia. – 2016. – № 3–4. – S. 6‒10 [Elektronnyi resurs]. – Rezhym dostupu: https://elibrary.ru/contents.asp?issueid=1680050&selid =27337740

Khawaja A. R., Khan F. B., Dar T. I. et al. Fosfomycin tromethamine. Antibiotic of choice in the female patient: A multicenter study // Central Europ. J. Urology. – 2015. – V. 68, N 3. – P. 371‒375. https://doi.org/10.5173 / ceju.2015.590

Fosfomitsyn: antybiotyk pershoi linii dlia peroralnoi terapii hostrykh neuskladnenykh infektsii sechovyvidnykh shliakhiv // Ratsionalna farmakoterapiia. – 2017. – Т. 4, № 45. – S. 100‒107 [Elektronnyi resurs]. ‒ Rezhym dostupu http://esparma.com.ua/uploads/280_Espa-focin.pdf

MacKenzie A. E., Caltabiano G., Kent T. C. et al. The antiallergic mast cell stabilizers lodoxamide and bufrolin as the first high and equipotent agonists of human and rat GPR35 // Mol. Pharmacol. – 2014. – V. 85, N 1. – Р. 91‒104. https://doi.org/10.1124/mol.113.089482

Palchevska T. A., Baula O. P., Salii O. O. ta in. Marketynhovi doslidzhennia asortymentu kontrastnykh likarskykh zasobiv, reprezentovanykh na farmatsevtychnomu rynku Ukrainy // Farmats. chasopys. – 2020. – № 1 (53). – S. 66‒74. https://doi.org/10.11603/2312-0967.2020.1.10980

Published
2021-08-26
How to Cite
Palchevska, T. A., Saliy, O. O., Baula, O. P., PalchevskyіK. V., & OnіshchukO. M. (2021). The role of excipients of trometamolum and meglumine in the formation of biopharmaceutical properties of medicinal products of various pharmacites. Farmatsevtychnyi Zhurnal, (4), 64-75. https://doi.org/10.32352/0367-3057.4.21.06
Section
Pharmaceutical technology